Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation.

Published byViktoria Göransson Modified over 5 years ago

Similar presentations

Presentation on theme: "Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation."— Presentation transcript:

1 Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation with metformin in pooled sera from human volunteers (A) and in a buffer solution containing DPP-IV (B), with added 110 pmol/l GLP-1(7–36)amide. Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation with metformin in pooled sera from human volunteers (A) and in a buffer solution containing DPP-IV (B), with added 110 pmol/l GLP-1(7–36)amide. Data are expressed as means ± SD. *P < 0.05 vs. control using Student’s unpaired t test and ANOVA. Edoardo Mannucci et al. Dia Care 2001;24: ©2001 by American Diabetes Association

Download ppt "Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation."

Similar presentations

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Antihyperglycemic therapy in type 2 diabetes: general recommendations

Antihyperglycemic therapy in type 2 diabetes: general recommendations
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.
Group differences (DKA vs

Group differences (DKA vs
The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.
Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.
Quantification and neutralization of VEGF in PDR vitreous.

Quantification and neutralization of VEGF in PDR vitreous.
Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.

Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Leptin and amylin signaling.

Leptin and amylin signaling.
Fatty acid incorporation into triglycerides, triglyceride content, glycerol release, and fatty acid efflux in wild-type and +CD36 myotubes. Fatty acid.

Fatty acid incorporation into triglycerides, triglyceride content, glycerol release, and fatty acid efflux in wild-type and +CD36 myotubes. Fatty acid.
GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.
An algorithm depicting the basic approach to the Charcot foot

An algorithm depicting the basic approach to the Charcot foot
Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.
Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.

Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.
FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.
Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Similar presentations

Ads by Google